Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.47 |
| ▸ | CASR | P41180 | 1/20 | 0.46 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30438293 | 0.89 | AURKA (0.46) | PTGESSLC1A2SLC1A1SLC1A3CASR | |
| SCHEMBL20917274 | 0.87 | SLC1A2 (0.40) | SLC1A2SLC1A1CASRMAPT | |
| SCHEMBL20917133 | 0.85 | FFAR1 (0.41) | CASR | |
| SCHEMBL20917044 | 0.84 | CACNA2D1 (0.51) | PTGESSLC1A2SLC1A1SLC1A3KCNK3 | |
| SCHEMBL20917284 | 0.82 | OPRK1 (0.42) | KMT2A | |
| SCHEMBL28415368 | 0.82 | SLC1A2 (0.54) | PTGESSLC1A2SLC1A1SLC1A3KCNK3 | |
| SCHEMBL20917069 | 0.81 | SLC1A2 (0.48) | PTGESSLC1A2SLC1A1SLC1A3KCNK3 | |
| SCHEMBL19553553 | 0.81 | PTGES (0.43) | PTGESKMT2ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL19553555 | 0.81 | PTGES (0.43) | PTGESKMT2ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL20917273 | 0.79 | SLC1A2 (0.48) | PTGESSLC1A2SLC1A1SLC1A3KCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111220-B2 | Propanamine derivatives for treating pain and pain related conditions | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2021-09-07 | — | — | US | disclosed |
| US-20200377464-A1 | PROPANAMINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-12-03 | — | — | US | disclosed |
| EP-3697754-A1 | PROPANAMINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-08-26 | — | — | EP | disclosed |
| WO-2019076904-A1 | PROPANAMINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377464-A1 | PROPANAMINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | CACNA1G, CACNA1B, CACNA1I | PTGES 733/4885SLC1A2 112/4885SLC1A1 169/4885 |
| US-11111220-B2 | Propanamine derivatives for treating pain and pain related conditions | CACNA1G, CACNA1B, CACNA1I | PTGES 733/4885SLC1A2 112/4885SLC1A1 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.